Table 2

PABAK – OS – 3-level interpretation
Drug Class Drug Proportion observed agreement Minor discrepancy Major discrepancy PABAK-OS 95%CI of PABAK-OS
NNRTI Etravirine 0.99 18 1 0.98 (0.96 - 1.01)
NRTI Abacavir 0.98 20 0 0.98 (0.96 - 1.01)
Didanosine 0.99 19 0 0.98 (0.96 - 1.01)
Lamivudine 1.00 1 0 1.00 (0.97 - 1.03)
Stavudine 0.99 16 0 0.99 (0.96 - 1.01)
Tenofovir 1.00 5 0 1.00 (0.97 - 1.02)
Zidovudine 0.98 21 0 0.98 (0.95 - 1.01)
PI Atazanavir/r 1.00 5 0 1.00 (0.97 - 1.02)
Darunavir/r 1.00 0 0 1.00 (0.97 - 1.03)
Lopinavir/r 1.00 2 0 1.00 (0.97 - 1.03)
Saquinavir/r 1.00 2 0 1.00 (0.97 - 1.03)
Tipranavir/r 1.00 4 0 1.00 (0.97 - 1.02)

Jiamsakul et al.

Jiamsakul et al. BMC Research Notes 2012 5:582   doi:10.1186/1756-0500-5-582

Open Data